M. Aihara

发表

Helicobacter pylori infection influences expression of genes related to angiogenesis and invasion in human gastric carcinoma cells.

K. Chayama, K. Haruma, N. Oue, 2003, Biochemical and biophysical research communications.

Mechanisms involved in Helicobacter pylori-induced interleukin-8 production by a gastric cancer cell line, MKN45

H. Wakebe, K. Matsushima, N. Mukaida, 1997, Infection and immunity.

New rat model induced by anti‐glomerular basement membrane antibody shows severe glomerular adhesion in early stage and quickly progresses to end‐stage renal failure

T. Hirano, K. Hattori, Yoshihisa Yamada, 2008, Pathology international.

In vitro Anti‐tumor Activity of Anti‐c‐erbB‐2 × Anti‐CD3ɛ Bifunctional Monoclonal Antibody

M. Shibamori, H. Okada, K. Imagawa, 1992, Japanese journal of cancer research : Gann.

Inhibition of rabbit gastric epithelial restoration by a water extract ofHelicobacter pylori: evidence using a cultured cell model

N. Sato, H. Miwa, A. Miyazaki, 1996, InflammoPharmacology.

Analysis of where and which types of proteinases participate in lysosomal proteinase processing using bafilomycin A1 and Helicobacter pylori Vac A toxin.

E. Kominami, K. Ishidoh, K. Imagawa, 1999, Journal of biochemistry.

[Tolvaptan, a vasopressin V2 receptor antagonist, is the world's first approved drug for treatment of autosomal dominant polycystic kidney disease (ADPKD)].

H. Fujiki, Y. Yamamura, K. Hattori, 2022, Nihon yakurigaku zasshi. Folia pharmacologica Japonica.

Functional and structural changes in end-stage kidney disease due to glomerulonephritis induced by the recombinant alpha3(IV)NC1 domain.

M. Muraguchi, T. Hirano, K. Hattori, 2010, Experimental animals.

Functional and Structural Changes in End-Stage Kidney Disease due to Glomerulonephritis Induced by the Recombinant α 3 ( IV ) NC 1 Domain

M. Muraguchi, T. Hirano, K. Hattori, 2010 .

Effect of Rebamipide, a Novel Antiulcer Agent, onHelicobacter pylori Adhesion to Gastric Epithelial Cells

Nobuhiro Fujii, Kenji Yokota, Hiroshi Isogai, 1998, Antimicrobial Agents and Chemotherapy.

Molecular analysis of suppression of interleukin-8 production by rebamipide in Helicobacter pylori-stimulated gastric cancer cell lines.

K. Matsushima, N. Mukaida, Y. Ohmoto, 1998, Digestive diseases and sciences.

Effects of rebamipide on production of several cytokines by human peripheral blood mononuclear cells.

Y. Ohmoto, K. Imagawa, Y. Funakoshi, 1998, Digestive diseases and sciences.

Tolvaptan Delays the Onset of End-Stage Renal Disease in a Polycystic Kidney Disease Model by Suppressing Increases in Kidney Volume and Renal Injury

H. Fujiki, Y. Yamamura, M. Ishikawa, 2014, The Journal of Pharmacology and Experimental Therapeutics.

Impact of tolvaptan add-on treatment on patients with heart failure requiring long-term congestion management: A retrospective cohort study using a medical claim database in Japan.

K. Kinugawa, Hiromi Sano, Miyuki Matsukawa, 2022, Journal of cardiology.

Tolvaptan Delays the Onset of End-Stage Renal Disease in a Polycystic Kidney Disease Model by Suppressing Increases in Kidney Volume and Renal Injury

H. Fujiki, Y. Yamamura, M. Ishikawa, 2014, The Journal of Pharmacology and Experimental Therapeutics.

[Tolvaptan, a vasopressin V2 receptor antagonist, is the world's first approved drug for treatment of autosomal dominant polycystic kidney disease (ADPKD)].

H. Fujiki, Y. Yamamura, Keisuke Nagano, 2022, Nihon yakurigaku zasshi. Folia pharmacologica Japonica.